Drug Research

AbbVie Inc said on Friday it had received European approval to market its drug for treatment of all six major forms of hepatitis C. The company said the approval of Maviret was…
Read More...

Biognosys announced that it has secured USD 5m funding from new and existing investors in an extended series C round. Biognosys’ contract research services and tools are successfully…
Read More...

Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce it has entered into a strategic drug discovery…
Read More...

LifeArc, the UK medical research charity previously known as MRC Technology, The Centre for Drug Research and Development (CDRD), and the Defence Science and Technology Laboratory…
Read More...

Seqirus announced the next major advancement in the use of cell-based technology at its state-of-the art manufacturing facility in Holly Springs, North Carolina. In an industry…
Read More...

Lannett Company announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Amantadine Hydrochloride Capsules…
Read More...

Numerate, Inc., a computational drug design company applying artificial intelligence (AI) at cloud scale to transform small molecule drug discovery, announced the formation of a…
Read More...

Selexis SA and TeneoBio announced that they have entered into a service agreement to advance the development of a new class of biologics, Human Heavy-Chain Antibodies (UniAbs) targeting…
Read More...

Novartis announced that the European Commission (EC) has approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna (nilotinib) Summary of Product Characteristics…
Read More...

Mylan announced the U.S. launch of Rasagiline Tablets, 0.5 mg and 1 mg, a generic version of the reference listed drug, Teva's Azilect Tablets. Mylan received final approval from the…
Read More...

Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., and Johns Hopkins University announced today that they have extended their drug discovery…
Read More...

New research conducted by scientists at the University of Sheffield into a drug candidate which could help to delay the onset of motor neurone disease has shown encouraging early…
Read More...

TaiGen Biotechnology has submitted a New Drug Application (NDA) for Taigexyn (Nemonoxacin)intravenous formulation to China Food and Drug Administration (CFDA). Taigexyn is a novel…
Read More...

BioPharma Services has successfully completed 3 inspections this month by the US FDA, with concurrent audits at both research centers in Toronto, Canada, and Columbia, Missouri. Over…
Read More...

Avista Pharma Solutions announced that Minneapolis Medical Research Foundation (MMRF) has selected Avista Pharma to manufacture an opioid-derived small molecule. The research is funded…
Read More...

US FDA has granted Orphan Drug Designation (ODD) for Abeona’s EB-101 gene therapy program for patients with dystrophic epidermolysis bullosa (DEB), including recessive dystrophic…
Read More...

Optibrium has entered into a collaboration with Imperial College London for developing new treatments for neglected diseases as part of a collaborative project with DNDi (Drugs for…
Read More...

The US FDA accepted Bristol-Myers Squibb supplemental BLA to extend the use of Opdivo (nivolumab) to patients with hepatocellular carcinoma (HCC) after prior sorafenib therapy. The FDA…
Read More...

PharmaMar has signed agreement with Eczacibasi Group to commercialize the marine-derived anticancer drug Aplidin (plitidepsin) in Turkey. Aplidin is PharmaMar´s second most advanced…
Read More...

Palladio Biosciences announced that it has acquired global rights to lixivaptan from Chiesi USA to  develop it for Polycystic Kidney Disease (PKD), an orphan kidney disease for which…
Read More...